## Alecensa (alectinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S F	MEMBER'S FIRST NAME:		
important for the review		ta, to support the autho	•	onal documentation that is it). Information contained in	
				URGEN1	
MEMBER INFORMATION LAST NAME:	V	FIRST NAME:			
LAST IVAIVIL.		FINST IVAIVIE.	1		
PHONE NUMBER:		DATE OF BIR	DATE OF BIRTH:		
STREET ADDRESS:					
CITY:	STATE:	STATE: ZIP CODE:			
PATIENT INSURANCE ID	NUMBER:				
	RESCRIBER, YOU WILL NEED TO SUBMIT			ES:	
	REPRESENTATIVE (IF APPL 'ATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMAT	ION				
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDR	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBEI	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER	FAX NUMBER:		
STREET ADDRESS:					
CITY:	STATE:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONT	OFFICE CONTACT PERSON:		
MEDICATION OR MEDIC	CAL DISPENSING INFORMA	ATION			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/RE		QUANTITY:	
NEW THERAPY DURATION OF THERAPY	(SPECIFIC DATES):	IF RENEWAL:	DATE THERAPY	INITIATED:	

Continued on next page.



## Alecensa (alectinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	R'S LAST NAME: MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTH	ER MEDICATIONS FOR THIS CONDITION	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
□ Non-small cell lung cancer (NSCLC)				
□ Other diagnosis:	ICD-10 Code(s):			
<b>3. REQUIRED CLINICAL INFORMATIO</b> PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINI	CAL INFORMATION TO SUPPORT A		
	patient as part of a treatment regimen s	pecified within a sponsored clinical		
Please provide documentation.	ALK-positive metastatic non-small cell l			
has the patient been previously trea	ated with Xalkori(crizotinib)?   Yes   No	o Please provide documentation.		
Has the patient been treated with an  ☐ Yes ☐ No Please provide docume	ny other the ALK inhibitor such as Zykad ntation.	lia (ceritinib) or Alunbrig (brigatinib)?		
Will Alcensa(alectinib) be used in the	e adjuvant setting?   Yes   No			
Has patient had a complete resectio T3 N1, T1-T3 N2, T4 N0-1)? ☐ Yes ☐	n of histologically confirmed Stage IB tu No Please provide documentation.	mors ≥ 4 cm to Stage IIIA(T2-T3 N0, T1-		
Did patient have negative margins 4 documentation.	-12 weeks prior to starting Alcensa(alect	:inib)? □ Yes □ No Please provide		
Does patient have an ECOG status of	f 0 or 1? □ Yes □ No			
Has patient had prior adjuvant radio	otherapy for NSCLC?   Yes   No Please	provide documentation.		
Has patient had prior treatment with documentation.	h other systemic anti-cancer therapies?	□ Yes □ No Please provide		
Are there any other comments, diag physician feels is important to this re	noses, symptoms, medications tried or feview?	ailed, and/or any other information the		
<b>Please note:</b> Not all drugs/diagnosis information is received.	are covered on all plans. This request ma	y be denied unless all required		



## Alecensa (alectinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D. Verification:	Date:			
you are not the intended recipient, you are hereby notified that any	mission contain confidential health information that is legally privileged. If disclosure, copying, distribution, or action taken in reliance on the contents formation in error, please notify the sender immediately (via return FAX)			

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

